APVO Logo

Aptevo Therapeutics Inc. (APVO) 

NASDAQ
Market Cap
$2.41M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
442 of 776
Rank in Industry
231 of 433

Largest Insider Buys in Sector

APVO Stock Price History Chart

APVO Stock Performance

About Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a …

Insider Activity of Aptevo Therapeutics Inc.

Over the last 12 months, insiders at Aptevo Therapeutics Inc. have bought $0 and sold $0 worth of Aptevo Therapeutics Inc. stock.

On average, over the past 5 years, insiders at Aptevo Therapeutics Inc. have bought $49.69M and sold $16.87M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 348,554 shares for transaction amount of $7.92M was made by TANG KEVIN C (10 percent owner) on 2020‑11‑06.

List of Insider Buy and Sell Transactions, Aptevo Therapeutics Inc.

2021-11-23Sale
921,336
12.987%
$11.25$10.37M-73.69%
2021-11-22Sale10 percent owner
255,331
5.9122%
$7.03$1.8M-30.86%
2021-11-19Sale10 percent owner
213,800
4.7422%
$7.59$1.62M-38.63%
2021-11-18Sale10 percent owner
369,533
8.1153%
$8.34$3.08M-44.69%
2020-11-06Purchase10 percent owner
348,554
7.5668%
$22.73$7.92M+8.23%
2020-11-05Purchase10 percent owner
1.25M
25.0765%
$18.78$23.5M+20.82%
2020-11-04Purchase10 percent owner
1.27M
24.3464%
$14.34$18.27M+50.91%
2019-08-16PurchaseSVP Operations, CMO
50,000
0.1097%
$0.76$38,000-25.67%
2019-08-12Purchasedirector
200,000
0.4342%
$0.76$151,040-25.24%
2019-07-29PurchaseBoard of Directors
110,030
0.2409%
$0.83$91,721-31.45%
2019-07-23PurchaseBoard of Directors
20,000
0.0452%
$0.90$17,992-34.35%
2019-07-22PurchaseBoard of Directors
60,000
0.1331%
$0.89$53,202-34.06%
2019-07-19PurchaseBoard of Directors
52,920
0.1212%
$0.90$47,480-33.33%
2019-07-18PurchaseBoard of Directors
28,808
0.0638%
$0.87$25,193-33.40%
2019-07-17PurchaseBoard of Directors
38,272
0.085%
$0.87$33,408-32.68%
2019-07-16PurchaseBoard of Directors
22,750
0.0486%
$0.85$19,324-33.41%
2019-07-11PurchaseBoard of Directors
29,382
0.0649%
$0.85$24,907-30.51%
2019-07-10Purchasedirector
37,838
0.0843%
$0.85$32,117-30.01%
2019-06-25PurchaseBoard of Directors
33,334
0.0753%
$0.90$30,001-33.16%
2019-06-14PurchasePresident and CEO
100,000
0.2219%
$0.88$88,000-30.63%

Insider Historical Profitability

8.23%
El-Hibri Fuaddirector
1124536
11.9363%
$0.26100
White Marvin LPresident and CEO
293603
3.1164%
$0.2651
Abdun-Nabi DanielBoard of Directors
109351
1.1607%
$0.2610
Maddux Randy JoeSVP Operations, CMO
75000
0.7961%
$0.2640
Harsanyi ZsoltBoard of Directors
50000
0.5307%
$0.2610

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Tower Research Capital$6,209.000.021,324-90.31%-$57,850.62<0.0001
BlackRock$4,174.000.01890-98.09%-$214,538.91<0.0001
Morgan Stanley$910.00<0.01194-98.29%-$52,423.50<0.0001
JPMorgan Chase$202.00<0.0143-97.73%-$8,709.49<0.0001
Qube Research & Technologies$469.00<0.01100New+$469.00<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.